Business
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical
About this update from Context Therapeutics Inc.
[{"type":"text","content":"Data demonstrated ONA-XR decreased proliferation in tumors with high PR+ at baseline in early breast cancer Two additional metastatic breast cancer clinical trials in progress also presented PHILADELPHIA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS). The Phase 0 open-label, single-arm, multicenter ONAWA (SOLTI-1802) trial conducted by Spanish cancer research group SOLTI, enrolled 10 patients with ER+/PR+/HER2- negative tumors and levels of the cell proliferation marker \"Ki67\" above 10% to evaluate ONA-XR by the rate of Complete Cell Cycle Arrest (CCCR) determined by Ki-67 (≤2.7%) when administered for three weeks prior to surgery (Abstract #511). Secondary endpoints of the trial included safety and correlating biological activity with immunohistochemistry (IHC) of tumor expression (ER, PR, Ser294-PgR, CD24, CD44, ALDH1, Ki-67), estradiol, and progesterone blood levels, and gene expression profile (NanoString nCounter® Breast 360TM panel). While no patients achieved a CCCR, tumor Ki-67 expression decreased in six patients, remained stable in one patient, and increased in three patients. Mean percentage decrease of Ki67 for tumors with baseline PR expression ≥90% (N=4) and","length":1934,"tagName":"div"}]